Geneva Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Geneva Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$326K	Buy	+2,528	New	+$304K	0.01%	593
2016 Q4	–	Sell	-8,415	Closed	-$734K	–	811
2016 Q3	$734K	Sell	8,415 -8,040	-49%	-$760K	0.01%	387
2016 Q2	$1.42M	Buy	16,455 +13,852	+532%	+$1.2M	0.03%	243
2016 Q1	$207K	Buy	+2,603	New	+$235K	﹤0.01%	605
2015 Q3	–	Sell	-4,507	Closed	-$557K	–	687
2015 Q2	$557K	Sell	4,507 -94,774	-95%	-$11.9M	0.01%	409
2015 Q1	$11.7M	Buy	+99,281	New	+$11.9M	0.21%	91

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geneva Advisors's VRTX Position: Q2 2017 in Review

Geneva Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2017: 2,528 shares worth $326K. The stake represents 0.01% of the portfolio and ranks #593 among its holdings. This is a return to the name: Geneva Advisors previously reported a position in VRTX as recently as Q3 2016.

Geneva Advisors first reported a position in VRTX in Q1 2015 and has held it in 6 quarters since. The position peaked at $11.7M in Q1 2015. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

Geneva Advisors held 2,528 shares of Vertex Pharmaceuticals worth $326K as of Q2 2017.
Vertex Pharmaceuticals was a new Geneva Advisors position in Q2 2017.
Vertex Pharmaceuticals made up 0.01% of Geneva Advisors's portfolio in Q2 2017, its #593 holding.
Geneva Advisors first reported a position in Vertex Pharmaceuticals in Q1 2015 and has held it in 6 quarters since.
Geneva Advisors's Vertex Pharmaceuticals position peaked at $11.7M in Q1 2015.
582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.